FTSE MIB
34.492,41 +44,84 (+0,13%) Dow Jones
38.686,32 +574,84 (+1,51%) Nasdaq
16.735,02 -2,06 (-0,01%) Nikkei 225
38.487,90 +433,77 (+1,14%) Petrolio
77,18 -0,73 (-0,94%) Bitcoin EUR
62.394,00 -897,89 (-1,42%)
Acrivon Therapeutics, Inc. (ACRV)
Dopo ore:
| Chiusura precedente | 7,57 |
| Aperto | 7,57 |
| Denaro | 7,62 x 300 |
| Domanda | 7,72 x 300 |
| Min-Max giorno | 7,54 - 8,10 |
| Intervallo di 52 settimane | 3,19 - 14,03 |
| Volume | |
| Media Volume | 777.277 |
| Capitalizzazione | 238,37M |
| Beta (mensile su 5 anni) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,89 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 22,38 |
GlobeNewswireAcrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as well as tumor types, most likely to respond to the CHK1/2 inhibitor ACR-368 ACR-368 OncoSignature assay being utilized in the registrational-intent Phase 2 trial of ACR-368 for patients with ovarian, endometrial, or bladder cancer WATERTOWN, Mass., Oct. 16, 2023 (
- GlobeNewswire
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced that the company approved a grant of equity awards under its 2023 Inducement Plan to tw
- GlobeNewswire
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
WATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced that two abstracts have been selected for poster presentations at the AACR-NCI-EO
